Kedrion Biopharma

Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.

Kedrion Biopharma - The Annual Report · Christian Sinibaldi

Product replacement Program I KEDRAB® Rabies Immune Globulin (Human)

Kedrion Biopharma · 4 of 30 · Christian Sinibaldi

MAESTrO: Kedrion Biopharma and Kamada receive FDA approval of

Human Albumin 200 g/l KEDRION Biopharma

Anekant Pharma Kedrion Products

EuropaBio - On #WorldHemophiliaDay 2020 we had the opportunity to

BPL & Kedrion – Jamieson

FSI invests in Kedrion

Hemolytic Disease of the Newborn / Suppression of Rh

MY WAY TO by Kedrion SpA